Skip to content
10-Q

Quarterly Report

KYMERA THERAPEUTICS, INC. KYMR

0001193125-26-193967

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 24, 2026 82.26M sh
Shares Diluted Q1 2026 · Mar 31, 2026 97.53M sh
Shares Diluted Q1 2026 · Mar 31, 2025 80.15M sh
Capex Q1 2026 · Mar 31, 2026 $434K
Capex Q1 2026 · Mar 31, 2025 $467K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$88.84M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$79.15M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $144.09M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $357.01M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $89.97M
Stockholders Equity Q1 2026 · Mar 31, 2026 $1.54B
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.58B
Stockholders Equity Q1 2026 · Mar 31, 2025 $786.23M
Stockholders Equity Q1 2026 · Dec 31, 2024 $835.62M
Current Liabilities Q1 2026 · Mar 31, 2026 $62.64M
Current Liabilities Q1 2026 · Dec 31, 2025 $83.21M
Total Liabilities Q1 2026 · Mar 31, 2026 $129.38M
Total Liabilities Q1 2026 · Dec 31, 2025 $163.15M
Current Assets Q1 2026 · Mar 31, 2026 $677.43M
Current Assets Q1 2026 · Dec 31, 2025 $871.21M
Total Assets Q1 2026 · Mar 31, 2026 $1.67B
Total Assets Q1 2026 · Dec 31, 2025 $1.74B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.71
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.82
Eps Basic Q1 2026 · Mar 31, 2026 −$0.71
Eps Basic Q1 2026 · Mar 31, 2025 −$0.82
Sga Expense Q1 2026 · Mar 31, 2026 $20.36M
Sga Expense Q1 2026 · Mar 31, 2025 $16.27M
Rd Expense Q1 2026 · Mar 31, 2026 $98.16M
Rd Expense Q1 2026 · Mar 31, 2025 $80.26M
Net Income Q1 2026 · Mar 31, 2026 −$69.23M
Net Income Q1 2026 · Mar 31, 2025 −$65.58M
Operating Income Q1 2026 · Mar 31, 2026 −$84.15M
Operating Income Q1 2026 · Mar 31, 2025 −$74.43M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $34.37M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $22.1M
Revenue Q1 2026 · Mar 31, 2026 $34.37M
Revenue Q1 2026 · Mar 31, 2025 $22.1M